Lynn Bjerke

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Florence I. Raynaud, Suzanne A. Eccles, Paul A. Clarke et al. · Cancer Research · 2007 · 352 citations · Full text

Medicine, Oncology, Pharmacology +10

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

Lynn Bjerke, Alan Mackay, Meera Nandhabalan et al. · Cancer Discovery · 2013 · 315 citations · Full text

Medicine, Genetics, Oncology +17

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

Sandrine Guillard, Paul A. Clarke, Robert te Poele et al. · Cell Cycle · 2009 · 76 citations · Full text

Life Sciences, Oncology, Pharmacology +17

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

Ilon Liu, Gustavo Alencastro Veiga Cruzeiro, Lynn Bjerke et al. · Cancer Cell · 2024 · 49 citations · Full text

Life Sciences, Neuroscience, Oncology +17

Chemical Genetics Reveals an RGS/G-Protein Role in the Action of a Compound

Kevin Fitzgerald, Svetlana Tertyshnikova, Lisa A. Schulte Moore et al. · PLoS Genetics · 2006 · 37 citations · Full text

Life Sciences, Genetics, Molecular Biology +17